Pharmacotherapy for cancer pain: an anaesthesiologist's viewpoint.
Cancer pain is prevalent and undertreated despite the availability of therapeutic options that, taken together are highly effective, economical and safe. Improved understanding of the pharmacology of chronically-administered opioids has resulted in reduced concerns about addiction and an increased emphasis on their use. The anaesthetist may play a pivotal role in cancer pain management by the provision of nerve blocks and other interventions, but, to be a truly effective consultant, must also be expert in all aspects of pharmacotherapy. A rationale for the development of pharmacologic expertise together with a review of assessment and pharmacologic management of cancer pain are provided.
Patt
R B
RB
University of Texas MD Anderson Cancer Center, Section of Pain and Symptom Management, Houston 77030.
D000700:Analgesics / Q000008:administration & dosage* / Q000009:adverse effects / Q000145:classification; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000145:classification; D000776:Anesthesiology; D006801:Humans; D009369:Neoplasms / Q000503:physiopathology*; D009293:Opioid-Related Disorders; D010146:Pain / Q000517:prevention & control*; D010819:Physician's Role; D019966:Substance-Related Disorders
D000700:Analgesics; D000701:Analgesics, Opioid